CD8A and neoplasm: Because CCL3, CCL4, and CCL5 signal through the CCR5 receptor, we next evaluated LLC tumor growth in CD8+ T cell–sufficient and –deficient mice treated with the FDA-approved CCR5 antagonist, maraviroc.